Abstracts tagged "RNA"

Abstract Number: 2687 • 2012 ACR/ARHP Annual Meeting
Modular Microarray Analysis Fails to Reveal a Significant Biological Effect of Vitamin D3 Treatment in Patients Participating in a Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Michaela Oswald¹, Cynthia Aranow², Diane L. Kamen³, Meggan C. Mackay⁴, Ellen A. Goldmuntz⁵, Betty Diamond⁶, Peter K. Gregersen⁷ and ALE02 Study Team⁸, ¹Laboratory of Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, NY, ³Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁴Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁵DAIT, NIAID/NIH, Bethesda, MD, ⁶Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, ⁷Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸NIAID/NIH Rm 6807, Bethesda, MD
Background/Purpose: Vitamin D modulates the immune response. Exposing normal PBMCs to activating SLE sera induces an interferon signature which can be inhibited by preexposure of…
Abstract Number: 2619 • 2012 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Cynthia Aranow¹, Maria Dall'era², Elena M. Massarotti³, Meggan C. Mackay⁴, Andreea Coca⁵, Fotios Koumpouras⁶, Marc C. Levesque⁷, W. Winn Chatham⁸, Megan E. B. Clowse⁹, Lisa G. Criscione-Schreiber¹⁰, Sherri Callahan¹¹, Ellen A. Goldmuntz¹², Lynette Keyes-Elstein¹³, Betty Diamond¹⁴ and Diane L. Kamen¹⁵, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁶Lupus Center of Excellence, West Penn Hospital, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Rheumatology, Duke University Health System, Durham, NC, ¹¹Dait, NIAID/NIH Rm 6807, Bethesda, MD, ¹²DAIT, NIAID/NIH, Bethesda, MD, ¹³Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, ¹⁵Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC
Background/Purpose: Exposure of normal PBMCs to1,25 OH vitamin D reverses the stimulatory effects of activating SLE sera on the interferon signature. Given that IFN is…
Abstract Number: 2572 • 2012 ACR/ARHP Annual Meeting
Molecular Signatures in SLE: Flare Vs. Infection
Meggan Mackay¹, Michaela Oswald², Jorge Sanchez-Guerrero³, Juan J. Lichuaco⁴, Cynthia Aranow⁵, Sean Kotkin⁶, Peter K. Gregersen⁷ and Betty Diamond⁸, ¹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ²Laboratory of Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ³UHN Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine, St. Luke's Medical Center, Quezon City, Philippines, ⁵Feinstein Institute for Medical Research, Manhasset, NY, ⁶Autoimmune & Musculoskeletal Disease, The Feinstein Institute for Medical Research, Manhasset, NY, ⁷Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ⁸Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY
Background/Purpose: Inability to distinguish between infection and the inflammatory response related to SLE disease activity using clinical judgment often compromises timely and effective treatment. Gene…
Abstract Number: 1529 • 2012 ACR/ARHP Annual Meeting
Upper Airway Gene Expression Profiling in Granulomatosis with Polyangiitis
Peter C. Grayson¹, Katrina Steiling², Paul A. Monach³, Ji Xiao⁴, Xiaohui Zhang², Yuriy Alekseyev², Stephano Monti⁴, Avrum Spira⁵ and Peter A. Merkel⁶, ¹Section of Rheumatology & the Clinical Epidemiology Unit, Boston University School of Medicine, Vasculitis Center, Boston, MA, ²Computational Biomedicine, Boston University Medical Center, Boston, MA, ³Rheumatology, Boston University, Boston, MA, ⁴Computational Biomedicine, Boston University Medial Center, Boston, MA, ⁵Computational Biomedicine, Boston University School of Medicine, Boston, MA, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Nasal disease occurs in the majority of patients with granulomatosis with polyangiitis (Wegener's, GPA) and is often a presenting symptom of the disease. The…
Abstract Number: 889 • 2012 ACR/ARHP Annual Meeting
Modeling Environmental and Genetic Determinants to Identify the Association of Risk Genes in Anti-Ro60-Mediated Injury: Relaxin Receptor I and Tumor Necrosis Factor
Joanne H. Reed¹, Paula S. Ramos², Jiri Zavadil³, Jill P. Buyon⁴ and Robert M. Clancy¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Pathology and Center for Health Informatics and Bioinformtics, New York University School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Fetuses exposed to maternal anti-Ro60 antibodies can develop cardiac conduction abnormalities and life threatening cardiomyopathy; manifestations of neonatal lupus (NL). Recent data support an injury…
Abstract Number: 524 • 2012 ACR/ARHP Annual Meeting
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts in Sjögren’s Syndrome
Indra Adrianto¹, Graham B. Wiley¹, John A. Ice¹, He Li¹, Jennifer A. Kelly², Astrid Rasmussen¹, Stuart B. Glenn³, Kimberly Hefner⁴, Donald U. Stone⁵, Raj Gopalakrishnan⁶, Glen D. Houston⁷, David M. Lewis⁸, Michael Rohrer⁶, James A. Lessard⁹, Juan-Manuel Anaya¹⁰, Barbara M. Segal¹¹, Nelson L. Rhodus¹², Lida Radfar¹³, John B. Harley¹⁴, Judith A. James², Courtney G. Montgomery¹, R. Hal Scofield¹⁵, Patrick M. Gaffney¹, Kathy Moser Sivils² and Christopher J. Lessard¹⁶, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁵Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁷Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁰School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹¹Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹²University of Minnesota, Minneapolis, MN, ¹³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. SS…
Abstract Number: 4 • 2012 ACR/ARHP Annual Meeting
Pro-Inflammatory Effect of Extracellular RNA On Synovial Fibroblasts From Patients with Rheumatoid Arthritis
Birgit Zimmermann¹, Silvia Fischer², Markus Rickert³, Stefan Rehart⁴, Angela Lehr⁵, Ulf Müller-Ladner⁶, Klaus T. Preissner² and Elena Neumann⁷, ¹Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²Dept of Biochemistry, Justus-Liebig-University of Giessen, Medical School, Giessen, Germany, ³Dept of Orthopedics and Orthopedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, ⁴Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, ⁵Dept Orthopedics and Trauma Surgery, Markus-Hospital, Frankfurt, Germany, ⁶Dept of Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ⁷Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany
Background/Purpose: Extracellular RNA (exRNA) is present in the serum of patients suffering of different kinds of cancer. exRNA influences physiological processes like blood coagulation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].